Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1701024

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Incontinence: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make it her policy to make an assessment of the potential impact of any proposed amendments to Part IX of the Drug Tariff on (a) patients with continence care needs, (b) continence care services, (c) the range of continence devices available to clinicians and patients and (d) new product development and innovation in medical devices in the continence sector.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21863
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>Part IX will remain a list of devices available to be prescribed in the community, via the FP10 prescription route. The Department believes that it is currently difficult to identify which devices are broadly comparable, and whether more expensive devices provide added value. The proposed amendments that were consulted on were intended to increase meaningful choice, not to decrease the choice for clinicians and patients. Comparison between products can increase awareness of different brands amongst prescribers, which can support small and medium sized businesses in entering the market.</p><p>The consultation response on the proposed amendments to Part IX is expected to be released in May 2024, which will outline the Government’s response. Any amendments that are taken forward will happen gradually, with review points and engagement with stakeholders, including industry, patient representatives, clinicians, and National Health Service organisations. We are aware that there are some very good devices in use, relied upon by clinicians and patients.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:34:23 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1701026

	registered interest
	date	15/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Bowel Cancer: Greater Manchester
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what recent assessment her Department has made of the adequacy of bowel cancer diagnosis services in (a) Stockport and (b) Greater Manchester.
	tabling member constituency	Stockport
	tabling member printed	Navendu Mishra
	uin	21865
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>The Department continues to take steps to improve early diagnosis for all cancers, which encompasses bowel cancer, and in all areas, including Stockport and Greater Manchester. The Department is working jointly with NHS England on implementing the Delivery Plan for Tackling the COVID-19 Backlog of Elective Care, which includes plans to spend more than £8 billion from 2022/23 to 2024/25 to help drive up and protect elective activity, including cancer diagnosis and treatment.</p><p>NHS England is working to meet the Faster Diagnosis Standard (FDS), which sets a target of 28 days from urgent referral by a general practitioner or screening programme to patients being told that they have cancer, or that cancer is ruled out. To achieve this target, NHS England has: streamlined bowel cancer pathways by implementing faecal immunochemical testing (FIT) triage for patients in primary and secondary care settings; implemented non-symptom specific pathways for patients; and opened community diagnostic centres across England, prioritising this capacity for cancer services. The latest published data from February 2024 shows FDS performance was 78.1% nationally. More specifically to bowel cancer, the latest published data shows that at a national level, the number of people diagnosed with bowel cancer has risen to 41,596 in 2021, compared to 37,702 diagnosed in 2019. Since the FIT kit was introduced into the bowel cancer screening programme in April 2019, national uptake has increased from 59.2% to 67.8%. the latest data for the North-West region shows that 64.3% of 60 to 74-year-olds completed their bowel screening in the first quarter of 2023/24.</p><p>In 2023 the NHS England’s Help Us Help You campaign urged people to take up the offer of bowel screening when invited, and the screening offer for the bowel screening programme is being gradually extended from age 60 down to 50 years old by 2025, ensuring more people are screened and potentially diagnosed with bowel cancer at the earliest stage.   NHS England is also now offering routine preventative bowel cancer screening to people with Lynch syndrome, with 94% of people on average receiving the test between 2021 and 2023, up from 47% in 2019.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 09:37:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	4811 label Biography information for Navendu Mishra

1699978

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment she has made of the potential impact of discontinuing funding for T1DE pilot schemes on the health and well-being of patients living with type 1 diabetes with disordered eating.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20895
	answer	answer is ministerial correction date of answer 18/04/2024 answer text <p>NHS England has provided funding for eight integrated care boards (ICBs) across the country to support the development and establishment of Type 1 Diabetes with Disordered Eating (T1DE) services in every National Health Service region. Funding has been provided on a pump prime basis, and the responsibility for the longer-term sustainable provision of care for these patients sits with the relevant integrated care system.</p><p>A nationally commissioned evaluation has shown the positive impact that the provision of T1DE services can have for patients, including reductions in HbA1c, which is linked to reduced rates of diabetes complications, and reduced rates of emergency admissions.</p><p>It’s the role of the ICBs to consider the health needs of their populations, in making decisions about the care that is provided. It is expected that ICB leads consider these evaluation findings alongside the risk to patient health and wellbeing of the discontinuation of service provision, as well as other local contextual factors in making decisions about the future provision of T1DE services.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 18/04/2024 12:53:21 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699979

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment her Department has made of the potential implications for its policies of the cost-benefit analysis of the T1DE pilot schemes carried out by NHS England.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20896
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20897 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1699980

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Diabetes: Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether she (a) has made and (b) plans to make an assessment of the potential merits of funding options to ensure the sustainability of T1DE services beyond the pilot phase.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20897
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>Evaluation by the National Health Service of the initial Type 1 Diabetes with Disordered Eating service (T1DE) pilot sites, in London and Wessex, demonstrated a mean reduction in HbA1c of between 2.3% to 2.5%. Assuming that this level of reduction is maintained, the lifetime quality-adjusted life year gain of these services was estimated at 1.49, which would be cost effective up to a net lifetime cost of £29,800-£44,800.</p><p>In response to these initial evaluation findings, NHS England expanded the T1DE programme, supporting provision of new services in an additional five sites from September 2022, expanding coverage to more areas of the country. It is expected that these services will generate further evaluation data to consolidate these early findings, which can be used to inform national and local policy decisions.</p><p>NHS England is drawing on learning from existing T1DE services, other emerging evidence and the findings of the recent parliamentary inquiry, to ensure all areas of the country are supported to improve care for those identified as having T1DE. The emergence of these future plans are subject to future spending review settlements for the NHS and level of funding from the NHS England budget allocated to T1DE.</p><p>NHS England are also working closely with the first wave of pilot sites including London to ensure that the newer services can benefit from their learning and experience when considering local funding options in advance of March 2025, when the national funding for the five new sites will come to an end.<strong><br> </strong></p><p>NHS England is assisting integrated care boards to develop local funding arrangements through the provision of evaluation data, a national programme of support workshops, and an online platform to share learning and good practice.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20896 question first answered 17/04/2024 15:22:42 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700034

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, if she will make a comparative assessment of the adequacy of the reasons the (a) National Institute for Health and Care Excellence has been unable and (b) Scottish Medicines Consortium has been able to recommend Enhertu for use on the NHS.
	tabling member constituency	Brighton, Pavilion
	tabling member printed	Caroline Lucas
	uin	20959
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) makes authoritative, evidence-based recommendations for the National Health Service in England on whether new licensed medicines should be routinely funded by the NHS, based on an assessment of their costs and benefits. Decisions on the availability of medicines in Scotland are a matter for the devolved administration.</p><p>The NICE published guidance in 2021 and 2023 recommending Enhertu, also known as trastuzumab deruxtecan, for the treatment of NHS patients with HER2-positive breast cancer through the Cancer Drugs Fund, and it is now available to eligible NHS patients in England in line with the NICE’s recommendations.</p><p>The NICE is currently evaluating Enhertu for the treatment of metastatic HER2-low breast cancer, and has not yet published final guidance. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process and publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:01:22 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	3930 label Biography information for Caroline Lucas

1700037

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health Services: Consultants
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many and what proportion of NHS consultants carried out work in the private sector in the most recent financial year for which data is available.
	tabling member constituency	Knowsley
	tabling member printed	Sir George Howarth
	uin	20900
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>The Department does not hold the information requested.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 17/04/2024 10:23:50 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	481 label Biography information for Sir George Howarth

1700039

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Disability Aids
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what data her Department holds on how many useable mobility aids and equipment are wasted in the NHS each year.
	tabling member constituency	Huddersfield
	tabling member printed	Mr Barry Sheerman
	uin	20866
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This commitment is then applied locally, taking into account local priorities, through local Green Plans.</p><p>NHS England also collaborates with the NHS Supply Chain to increase availability of reusable products, and supports local NHS organisations through the publication of guidance and resources to help with implementing changes.</p><p>Furthermore, the Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department’s Design for Life Programme works with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery becoming the default. The Department recognises we will need to define future data requirements and align digital infrastructure to improve the gathering of core data, such as how products are eventually disposed. The Department’s intention is to publish a roadmap later this year, to articulate our relevant findings and plans moving forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20867 question first answered 17/04/2024 14:13:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	411 label Biography information for Mr Barry Sheerman

1700040

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Disability Aids: Waste Disposal
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what information her Department holds on where the NHS disposes of (a) crutches, (b) wheelchairs and (c) other mobility equipment.
	tabling member constituency	Huddersfield
	tabling member printed	Mr Barry Sheerman
	uin	20867
	answer	answer is ministerial correction date of answer 17/04/2024 answer text <p>As set out in the Delivering a Net Zero National Health Service report, published in October 2020, the NHS is committed to reducing its environmental impact, including by increasing the reuse and recycling of medical equipment. This commitment is then applied locally, taking into account local priorities, through local Green Plans.</p><p>NHS England also collaborates with the NHS Supply Chain to increase availability of reusable products, and supports local NHS organisations through the publication of guidance and resources to help with implementing changes.</p><p>Furthermore, the Department published the inaugural Medical Technology Strategy in February 2023, which included a focus on improving resource efficiency. The Department’s Design for Life Programme works with industry, the health and care sector, and academic partners to develop medical technology systems that support reuse, remanufacture, and material recovery becoming the default. The Department recognises we will need to define future data requirements and align digital infrastructure to improve the gathering of core data, such as how products are eventually disposed. The Department’s intention is to publish a roadmap later this year, to articulate our relevant findings and plans moving forward.</p> answering member constituency Pendle answering member printed Andrew Stephenson grouped question UIN 20866 question first answered 17/04/2024 14:13:08 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	411 label Biography information for Mr Barry Sheerman

1700068

	registered interest
	date	12/04/2024
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Trastuzumab Deruxtecan
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether NICE is taking steps to make Enhertu available to the National Health Service to treat incurable HER2-low secondary breast cancer.
	tabling member constituency	South Holland and The Deepings
	tabling member printed	Sir John Hayes
	uin	20865
	answer	answer is ministerial correction date of answer 16/04/2024 answer text <p>The National Institute for Health and Care Excellence (NICE) is currently developing guidance for the National Health Service on whether Enhertu can be recommended for routine NHS funding, based on an assessment of the costs and benefits. The NICE was unfortunately unable to recommend Enhertu as a clinically and cost-effective use of NHS resources in its final draft guidance published on 5 March 2024. Stakeholders have had an opportunity to appeal against the NICE’s draft recommendations, and the NICE will consider any appeals through the established process, and will publish final guidance in due course.</p> answering member constituency Pendle answering member printed Andrew Stephenson question first answered 16/04/2024 15:03:45 answering member 4044 label Biography information for Andrew Stephenson
	tabling member	350 label Biography information for Sir John Hayes